GlassScriptPhysician profile
Cindy Corpier
NPI 1992790604
$3,732.00
in general payments reported to CMS, 2019-2025
31 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $195 · 2021: $178 · 2022: $357 · 2023: $524 · 2024: $996 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $410.76 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $407.31 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $325.92 | 2019-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $304.56 | 2019-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $256.74 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $240.38 | 2019-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.29 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $151.71 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $142.45 | 2021-2025 | |
| Novo Nordisk INC | $134.64 | 2021-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $130.53 | 2019-2024 | Veltassa |
| Ardelyx, INC. | $110.24 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $102.10 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $97.29 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $94.66 | 2020-2025 | Acthar |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.07 | 2019-2025 | |
| Travere Therapeutics, INC. | $88.70 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $86.01 | 2019 | |
| Recor Medical INC | $60.61 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Calliditas Therapeutics US INC. | $53.94 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $51.83 | 2024 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $33.10 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $23.51 | 2024 | Givlaari |
| Scpharmaceuticals INC. | $23.03 | 2025 | |
| Kyowa Kirin, INC. | $19.72 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.20 | 2020 | |
| Apellis Pharmaceuticals, INC. | $16.80 | 2025 | Empaveli |
| Renalytix Ai, INC. | $15.98 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.56 | 2025 | |
| Glaxosmithkline, LLC. | $14.91 | 2023 | Benlysta |
| Chiesi USA, INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Corpier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.